Omada Health Makes a Splashy Nasdaq Debut: Digital Health’s Second Act in 2025 – ( $OMDA $NVDA $TDOC )

A Fresh Face on Wall Street

On a lively Friday, June 6, Omada Health (OMDA) stepped onto the Nasdaq stage, becoming the second major digital health company to go public in 2025—a year that’s already shaping up as a comeback for healthcare IPOs. Omada’s shares opened at $23, quickly soaring to $28 before settling at $23 by the closing bell—a 21% leap from its IPO price of $19 per share. The company’s debut raised $150 million, pegging its market value at a healthy $1.3 billion.

What Makes Omada Tick?

Founded in 2011, Omada Health specializes in virtual care between doctor visits, helping people manage chronic conditions like diabetes, hypertension, obesity, and musculoskeletal issues. Rather than chasing the latest pharmaceutical fads, Omada has carved out its niche by focusing on clinical guidance and behavioral support—especially for weight management. Notably, the company has sidestepped the buzz around GLP-1 weight loss drugs, instead offering programs that complement such medications with coaching and nutritional advice.

CEO Sean Duffy, in a recent interview, quipped that while the GLP-1 market is “tempting,” Omada prefers to be the steady hand guiding patients through the ups and downs of chronic disease management, rather than riding the rollercoaster of drug shortages and regulatory shakeups. “Our members want human support,” Duffy said, “not just a chatbot cheering them on”.

A Pandemic-Proof Business Model

Omada’s growth story accelerated during the pandemic, as virtual care became a necessity rather than a novelty. The company expanded its reach through partnerships with major employers, pharmacy benefit managers like CVS and Cigna, and device makers such as Abbott, whose glucose monitors are now a staple for Omada’s diabetic members.Today, Omada serves over 2,000 clients and boasts more than 679,000 active members in its programs.

Show Me the Numbers

• Q1 2025 revenue: $55 million (up 57% year-over-year)

• 2024 full-year revenue: $169.8 million (up 38% from 2023)

• Q1 2025 net loss: $9.4 million (down from $19 million in Q1 2024)

Despite its impressive growth, Omada is still chasing profitability—a common theme among digital health upstarts. The company’s losses are narrowing, and Duffy is optimistic that new investors will help “rewrite the story of chronic disease” in America.

Who’s Backing Omada?

Omada’s largest pre-IPO shareholder is Revelation Partners, with other heavy hitters like US Venture Partners, Andreessen Horowitz, and Fidelity’s FMR LLC each holding around 10%. The IPO itself was shepherded by Wall Street stalwarts Morgan Stanley, Goldman Sachs, and J.P. Morgan.

Looking Ahead

With its Nasdaq debut, Omada Health isn’t just raising capital—it’s signaling that digital health is back in vogue, and perhaps here to stay. As the sector shakes off its post-pandemic hangover, Omada’s blend of technology, human touch, and clinical rigor could set the tone for the next wave of healthcare innovation.

Now, with a fresh ticker symbol (OMDA) and a billion-dollar valuation, Omada Health is ready to show Wall Street—and the world—that managing chronic illness can be as much about encouragement and data as it is about prescriptions and procedures. And if the first day’s trading is any indication, investors are ready to cheer them on.

NOW CHECK OUT IOTAIRx

IOTAIRx is a digital health company bringing unmatched accuracy with Rx-optimized AI tools and processes automation at affordable levels into any clinical practice. A proven AI-based platform delivering secured, automated and advanced patient engagement; connecting patients seamlessly, capturing real time vitals and information across populations while minimizing critical care team resources. Their mission is to break down barriers in healthcare by enabling seamless care for underserved patient populations with minimal clinical staff involvement. Through innovative virtual care models, they deliver best practices that enhance quality, improve accessibility, and reduce costs for both patients and providers.

As a member of the NVIDIA Inception Program, IOTAIRx is leveraging NVIDIA’s AI Tech Stack—including NeMo framework, NVIDIA AI Blueprints, NIM, and Project MONAI (a PyTorch-based framework for healthcare imaging)—to develop custom models and agentic AI workflows.
By integrating cutting-edge AI technologies and multimodal models, IOTAIRx is pioneering a transformative shift in healthcare. This approach enables faster, more accurate diagnoses at the point of care, reducing diagnostic errors and improving patient outcomes while lowering healthcare costs.

TDOC

Teladoc Health (NYSE: TDOC), the global leader in virtual care, announced (April 30) it has acquired UpLift, an innovative and tech-enabled provider of virtual mental health therapy, psychiatry and medication management services.  The acquisition supports the company’s strategy to further enhance its leadership position in virtual mental health, including the ability for consumers served by its BetterHelp segment to access benefits coverage for mental health services. UpLift serves the health plan market and has arrangements covering over 100 million lives, a network of over 1,500 mental health professionals, important capabilities and a talented team.